Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 166

1.

Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.

van Besien K, Dew A, Lin S, Joseph L, Godley LA, Larson RA, Odenike T, Rich E, Stock W, Wickrema A, Artz AS.

Leuk Lymphoma. 2009 Nov;50(11):1809-17. doi: 10.3109/10428190903200790.

PMID:
19821799
[PubMed - indexed for MEDLINE]
2.

High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.

Liga M, Triantafyllou E, Tiniakou M, Lambropoulou P, Karakantza M, Zoumbos NC, Spyridonidis A.

Biol Blood Marrow Transplant. 2013 Jan;19(1):75-81. doi: 10.1016/j.bbmt.2012.07.021. Epub 2012 Aug 4.

PMID:
22871557
[PubMed - indexed for MEDLINE]
4.

An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.

Marsh RA, Kim MO, Liu C, Bellman D, Hart L, Grimley M, Kumar A, Jodele S, Myers KC, Chandra S, Leemhuis T, Mehta PA, Bleesing JJ, Davies SM, Jordan MB, Filipovich AH.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1625-31. doi: 10.1016/j.bbmt.2013.09.001. Epub 2013 Sep 10.

PMID:
24035782
[PubMed - indexed for MEDLINE]
5.

Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.

El-Cheikh J, Vazquez A, Crocchiolo R, Furst S, Calmels B, Castagna L, Lemarie C, Granata A, Ladaique P, Oudin C, Faucher C, Chabannon C, Blaise D.

Am J Hematol. 2012 Dec;87(12):1074-8. doi: 10.1002/ajh.23319. Epub 2012 Aug 22.

PMID:
22911907
[PubMed - indexed for MEDLINE]
6.

Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.

Lush RJ, Haynes AP, Byrne J, Cull GM, Carter GI, Pagliuca A, Parker JE, Mufti G, Mahendra P, Craddock CF, Lui Yin JA, Garg M, Prentice HG, Potter MN, Russell NH.

Cytotherapy. 2001;3(3):203-10.

PMID:
12171727
[PubMed - indexed for MEDLINE]
7.

The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.

Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A, Clark FJ, Hunt L, Yin J, Fuller S, Vandenberghe E, Marsh J, Littlewood T, Smith GM, Culligan D, Hunter A, Chopra R, Davies A, Towlson K, Williams CD.

Blood. 2002 Nov 1;100(9):3108-14.

PMID:
12384406
[PubMed - indexed for MEDLINE]
Free Article
8.

Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.

Das-Gupta EP, Russell NH, Shaw BE, Pearce RM, Byrne JL.

Biol Blood Marrow Transplant. 2007 Jun;13(6):724-33.

PMID:
17531783
[PubMed - indexed for MEDLINE]
9.

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.

Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S.

Blood. 2000 Oct 1;96(7):2419-25.

PMID:
11001893
[PubMed - indexed for MEDLINE]
Free Article
10.

Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.

Cull GM, Haynes AP, Byrne JL, Carter GI, Miflin G, Rebello P, Hale G, Waldmann H, Russell NH.

Br J Haematol. 2000 Mar;108(4):754-60.

PMID:
10792280
[PubMed - indexed for MEDLINE]
11.

Impact of T cell chimerism on clinical outcome in 117 patients who underwent allogeneic stem cell transplantation with a busulfan-containing reduced-intensity conditioning regimen.

Saito B, Fukuda T, Yokoyama H, Kurosawa S, Takahashi T, Fuji S, Takahashi N, Tajima K, Kim SW, Mori S, Tanosaki R, Takaue Y, Heike Y.

Biol Blood Marrow Transplant. 2008 Oct;14(10):1148-55. doi: 10.1016/j.bbmt.2008.07.013.

PMID:
18804045
[PubMed - indexed for MEDLINE]
12.

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.

Faulkner RD, Craddock C, Byrne JL, Mahendra P, Haynes AP, Prentice HG, Potter M, Pagliuca A, Ho A, Devereux S, McQuaker G, Mufti G, Yin JL, Russell NH.

Blood. 2004 Jan 15;103(2):428-34. Epub 2003 Sep 11.

PMID:
12969983
[PubMed - indexed for MEDLINE]
Free Article
13.

Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.

Rupa-Matysek J, Lewandowski K, Nowak W, Sawiński K, Gil L, Komarnicki M.

Transplant Proc. 2011 Jun;43(5):1915-23. doi: 10.1016/j.transproceed.2011.02.011.

PMID:
21693300
[PubMed - indexed for MEDLINE]
14.

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.

Pérez-Simón JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, García-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, Parker A, Leon A, Yong K, Sureda A, Hunter A, Sierra J, Goldstone AH, Linch DC, San Miguel JF, Mackinnon S; Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation.

Blood. 2002 Nov 1;100(9):3121-7.

PMID:
12384408
[PubMed - indexed for MEDLINE]
Free Article
15.

Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.

Rzepecki P, Sarosiek T, Szczylik C.

Jpn J Clin Oncol. 2006 Jan;36(1):46-9. Epub 2006 Jan 19.

PMID:
16423840
[PubMed - indexed for MEDLINE]
Free Article
16.

Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes.

Lim ZY, Pearce L, Ho AY, Barber L, Ingram W, Usai M, Tobal K, Devereux S, Pagliuca A, Mufti GJ.

Br J Haematol. 2007 Aug;138(4):517-26. Epub 2007 Jun 29.

PMID:
17608767
[PubMed - indexed for MEDLINE]
17.

Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.

Dey BR, McAfee S, Colby C, Sackstein R, Saidman S, Tarbell N, Sachs DH, Sykes M, Spitzer TR.

Biol Blood Marrow Transplant. 2003 May;9(5):320-9.

PMID:
12766882
[PubMed - indexed for MEDLINE]
18.

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, Geary J, Thuraisundaram D, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S.

Blood. 2002 Feb 1;99(3):1071-8.

PMID:
11807015
[PubMed - indexed for MEDLINE]
Free Article
19.

Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.

Kumar AJ, Hexner EO, Frey NV, Luger SM, Loren AW, Reshef R, Boyer J, Smith J, Stadtmauer EA, Levine BL, June CH, Porter DL, Goldstein SC.

Biol Blood Marrow Transplant. 2013 Jul;19(7):1094-101. doi: 10.1016/j.bbmt.2013.04.021. Epub 2013 Apr 28.

PMID:
23635453
[PubMed - indexed for MEDLINE]
20.

Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.

Devine SM, Sanborn R, Jessop E, Stock W, Huml M, Peace D, Wickrema A, Yassine M, Amin K, Thomason D, Chen YH, Devine H, Maningo M, van Besien K.

Bone Marrow Transplant. 2001 Sep;28(6):557-62.

PMID:
11607768
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk